Psychiatry Research
Volume 111, Issue 1 , Pages 11-20 , 5 August 2002

Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder

  • Carla M. Canuso

      Affiliations

    • Commonwealth Research Center, Boston, MA 02115, USA
    • Harvard Department of Psychiatry at the Massachusetts Mental Health Center, 74 Fenwood Road, Boston, MA 02115, USA
    • Harvard Medical School, Boston, MA 02115, USA
    • Corresponding Author InformationCorresponding author. Massachusetts Mental Health Center, 74 Fenwood Road, Boston, MA 02115, USA. Tel.: +617-626-9633; fax: +617-734-6206
    • ,
  • Jill M. Goldstein

      Affiliations

    • Harvard Department of Psychiatry at the Massachusetts Mental Health Center, 74 Fenwood Road, Boston, MA 02115, USA
    • Harvard Medical School, Boston, MA 02115, USA
    • Massachusetts General Hospital, Boston, MA 02115, USA
    • Harvard Institute for Psychiatric Epidemiology and Genetics, Boston, MA 02115, USA
    • ,
  • Joanne Wojcik

      Affiliations

    • Commonwealth Research Center, Boston, MA 02115, USA
    • Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Ree Dawson

      Affiliations

    • Commonwealth Research Center, Boston, MA 02115, USA
    • Frontier Science Technology, Boston, MA 02115, USA
    • ,
  • Danielle Brandman

      Affiliations

    • Commonwealth Research Center, Boston, MA 02115, USA
    • ,
  • Anne Klibanski

      Affiliations

    • Harvard Medical School, Boston, MA 02115, USA
    • Massachusetts General Hospital, Boston, MA 02115, USA
    • ,
  • Joseph J. Schildkraut

      Affiliations

    • Commonwealth Research Center, Boston, MA 02115, USA
    • Harvard Department of Psychiatry at the Massachusetts Mental Health Center, 74 Fenwood Road, Boston, MA 02115, USA
    • Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Alan I. Green

      Affiliations

    • Commonwealth Research Center, Boston, MA 02115, USA
    • Harvard Department of Psychiatry at the Massachusetts Mental Health Center, 74 Fenwood Road, Boston, MA 02115, USA
    • Harvard Medical School, Boston, MA 02115, USA

Received 29 August 2001 ,Revised 29 April 2002 ,Accepted 6 May 2002.

References 

  1. American Psychiatric Association, 1997. Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry 154, Suppl. 1–63.
  2. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine vs. placebo and haloperidol: acute phase results in the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111–123
  3. Beaumont PJV, Gelder MG, Friesen HG, Harris GW, MacKinnon PCB, Mandelbrote BM, et al. The effects of phenothiazines on endocrine function: I. British Journal of Psychiatry. 1974;124:413–419
  4. Bunker MT, Marken PA, Schneiderhan ME, Ruehter VL. Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. Journal of Child and Adolescent Psychopharmacology. 1997;7:65–69
  5. Canuso CM, Hanau M, Jhamb KK, Green AI. Olanzapine use in women with antipsychotic-induced hyperprolactinemia. American Journal of Psychiatry. 1998;155:1458
  6. Carter DA, McGarrick GM, Norton KR, Paykel ES, Prysor-Jones RA. The effect of chronic neuroleptic treatment on gonadotropin release. Psychoneuroendocrinology. 1982;7(2–3):201–207
  7. Casey DE. ‘Seroquel’ (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Expert Opinion on Investigational Drugs. 1996;5:939–957
  8. Daniel DG, Copeland LF. Ziprasidone: comprehensive overview and clinical use of novel antipsychotic. Expert Opinion on Investigational Drugs. 2000;9(4):819–828
  9. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Canadian Journal of Psychiatry. 1993;(Supp) 38:S80–S88
  10. Ferin, M., Jewlewicz, R., Warren, M., 1993. The neuroendocrine component: the hypothalamic-pituitary unit. The Menstrual Cycle Physiology, Reproductive Disorders, and Infertility. Oxford University Press, New York, pp. 8–24.
  11. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV. Washington: APA Press; 1996;
  12. Foord SM, Peters JR, Dieguez C, Scanlon MF, Hall R. Dopamine receptors on intact anterior pituitary cells in culture: functional association with the inhibition of prolactin and thyrotropin. Endocrinology. 1983;112:1567–1577
  13. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. Journal of Nervous and Mental Disease. 1982;170:463–467
  14. Grace AA. Phasic vs. tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41:1–24
  15. Green AI, Brown WA. Prolactin and neuroleptic drugs. Neurology Clinics. 1988;6:213–232
  16. Harlow BL, Cohen LS, Otto MW, Spiegelman D, Cramer DW. Prevalence and predictors of depressive symptoms in older premenopausal women: the Harvard Study of Moods and Cycles. Archives of General Psychiatry. 1999;56(5):418–424
  17. Hoff AL, Wieneke M, Horon R, Blankfeld H, Espinoza S, Faustman WO, et al. Estrogen levels relate to neuropsychological function in female schizophrenics (Abstract). Schizophrenia Research. 1997;24:107–108
  18. Huber TJ, Rollnik J, Wilhelms J, von zur Muhlen A, Emrich HM, Schneider U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology. 2001;26:27–53
  19. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. New England Journal of Medicine. 1993;329(19):1383–1388
  20. Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S. Clozapine: plasma levels and prolactin response. Psychopharmacology. 1981;73:184–187
  21. Kuczmarski RJ, Carrol MD, Flegal KM, Troiano RP. Varying body mass index cutoff points to describe overweight prevalence among US adults. Obesity Research. 1997;5:542–548
  22. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophrenia Research. 1996;20:247–252
  23. Kuruvilla A, Peedicayil J, Sriiiikrishna G, Kuruvilla K, Kanagasabapathy AS. A study of serum prolactin in schizophrenia: comparison of males and females. Clinical and Experimental Pharmacology and Physiology. 1992;19:603–606
  24. Lui JH. Hypothalamic amenorrhea: clinical perspectives, pathophysiology, and management. American Journal of Obsterics and Gynecology. 1990;163:1732–1736
  25. Magharious W, Goff DC, Amico E. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Research. 1998;77(3):159–166
  26. Marken PA, Haykel RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clinical Pharmacology. 1992;11(10):851–856
  27. Meltzer HY. Long-term effects of neuroleptic drugs on the neuroendocrine system. In:  Kemali D,  Racagni G editor. Chronic Treatments in Neuropsychiatry: Advances in Biochemical Psychopharmacology. New York: Raven Press; 1985;p. 59–68
  28. Moghaddam B, Sesack SR. Cellular interactions in the pre-frontal cortex: a major focus for schizophrenia research. In:  Dickstein LJ,  Riba MB,  Oldham JM editor. American Psychiatric Press Review of Psychiatry. 15:Washington, DC: American Psychiatric Association; 1996;p. 351–372
  29. Oades RD, Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology. 1994;19(4):373–385
  30. Olefski JM. Obesity. In:  Isselbacher KJ,  Braunwald E,  Wilson JD,  Martin JB,  Fauci AS,  Kasper DL editor. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 1992;p. 446–452
  31. Polishuk WZ, Kulcsar S. Effects of chlorpromazine on pituitary function. Journal of Clinical Endocrinology. 1956;16:292–293
  32. Prentice DS, Deakin JFW. Role of neuroleptic drugs and organic mechanisms in the aetiology of menstrual irregularities in schizophrenic women. Schizophrenia Research. 1992;6:114
  33. Riecher-Rossler A, Hafner H, Stunbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology?. Schizophrenia Bulletin. 1994;20:203–214
  34. Riecher-Rossler A, Hafner H, Dutsch-Strobel A, Stunbaum M. Gonadal function and its influence on psychopathology: a comparison of schizophrenia and non-schizophrenic female inpatients. Archives of Women's Mental Health. 1998;1:15–26
  35. Ripley HS, Papanicolaou GN. The menstrual cycle with vaginal smear studies in schizophrenia, depression and elation. American Journal of Psychiatry. 1941;98(4):567–573
  36. Sandison RA, Whitelaw E, Currie JD. Clinical trials with mellaril (TP21) in the treatment of schizophrenia: a two year study. Journal of Mental Science. 1960;106:732–741
  37. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophrenia Bulletin. 1990;16:185–194
  38. Shader RI, Nahum JP, DiMascio A. Amenorrhea. In:  Shader RI,  DiMascio A editor. Psychotropic Drug Side Effects: Clinical and Theoretical Perspectives. Baltimore: Williams and Wilkins; 1970;p. 10–15
  39. Smith S, Wheeler MJ, Murray R, O'Keane V. The effect of antipsychotic-induced hyperprolactinemia on the hypothalamic-pituitary-gonadal axis. Journal of Clinical Psychopharmacology. 2002;22(2):109–114
  40. Sullivan G, Lukoff D. Sexual side effects of antipsychotic medication: evaluation and interventions. Hospital and Community Psychiatry. 1990;41:1238–1241
  41. Teitz, N.W., 1990. Clinical Guide to Laboratory Tests. W.B. Saunders, Philadelphia.
  42. Yazigi RA, Quintero CH, Salameh WA. Prolactin disorders. Fertility and Sterility. 1997;67:215–225

PII: S0165-1781(02)00123-3

Psychiatry Research
Volume 111, Issue 1 , Pages 11-20 , 5 August 2002

Article Tools

* Image Usage & Resolution